<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02764697</url>
  </required_header>
  <id_info>
    <org_study_id>TBUC 10012015</org_study_id>
    <nct_id>NCT02764697</nct_id>
  </id_info>
  <brief_title>Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients</brief_title>
  <official_title>Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampa Bay Uveitis Center, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampa Bay Uveitis Center, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uveitis represents a heterogeneous group of diseases that results from ocular inflammatory
      reaction involving ocular tissue and vasculature. The inflammation usually causes pain,
      redness, photophobia and blurred vision. This inflammation, is typically treated with
      regional or systemic therapy. The regional therapy typically consists of topical
      corticosteroids or periocular or regional corticosteroids. Regional therapy can lead to a
      steroid response glaucoma, which is increased intraocular pressure.This pilot study aims to
      evaluate the possible effectiveness of H.P. Acthar in patients with active ocular
      inflammatory disease, and currently on treatment for glaucoma or have a history of glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uveitis represents a heterogeneous group of diseases that results from ocular inflammatory
      reaction involving ocular tissue and vasculature. The inflammation usually causes pain,
      redness, photophobia and blurred vision.

      H.P Acthar Gel stimulate the adrenal cortex to secrete cortisol. Additionally H.P. Acthar gel
      is also reported to bind to melanocortin receptors. Melanocortin receptor activation has been
      shown to exert marked anti-inflammatory and immune-modulatory effects in animal studies, by
      modulating pro inflammatory cytokines, followed by induction of anti- inflammatory mediators
      and subsequent leukocyte migration. Specifically melanocortins down regulate Tumor Necrosis
      Factor (TNF) alpha, Interleukin (IL) -2, Interferon gamma and T-cell proliferation and
      upregulates IL-10 and regulatory T cells. For this reason H.P. Acthar is an approved
      treatment for ocular inflammatory disease.

      Ocular inflammatory disease is typically treated with regional or systemic therapy. The
      regional therapy typically consists of topical corticosteroids or periocular or regional
      corticosteroids. Regional therapy can lead to a steroid response glaucoma, which is increased
      intraocular pressure.This pilot study aims to evaluate the possible effectiveness of H.P.
      Acthar in patients with active ocular inflammatory disease, and currently on treatment for
      glaucoma or have a history of glaucoma.

      Subjects will be treated with H P Acthar subcutaneous gel, 40 U/ml, given twice weekly x 8
      weeks, followed by once weekly x 4 weeks: a total 20 doses with the same cumulative units to
      be administered, using the approved route, with the option to do 4 additional doses if
      resolution is incomplete.

      This will be a prospective open-label, non-randomized pilot study: 12 week treatment for
      active non-infectious uveitis, endpoint assessment and safety assessment; additional 12 week
      assessment for uveitis activity/quiescence and safety assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Actual">December 20, 2016</completion_date>
  <primary_completion_date type="Actual">December 7, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Photographic Haze Reduced to Grade 0 or Down 2 Steps Documented With Fundus Photography</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Subjects will have fundus photography at baseline and 12 weeks. Intermediate uveitis is graded by haze; it is done using the photographic scale: grades 0-4 (lower values are a better outcome), utilized by the SUN criteria, based on the Nussenblatt photographic vitreous haze scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Improvement of Macular Edema</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinically Significant Uveitic Macular Edema: Clinical Improvement of Macular Edema with OCT Documentation of central foveal thickness &lt; 300 microns</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Uveitis</condition>
  <condition>Anterior Uveitis</condition>
  <condition>Intermediate Uveitis</condition>
  <condition>Posterior Uveitis</condition>
  <condition>Scleritis</condition>
  <condition>Clinically Significant Macular Edema</condition>
  <arm_group>
    <arm_group_label>H.P. Acthar Subcutaneous Gel Injection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H.P. ACTHAR SUBCUTANEOUS GEL INJECTION</intervention_name>
    <description>Subcutaneous injection twice weekly</description>
    <arm_group_label>H.P. Acthar Subcutaneous Gel Injection</arm_group_label>
    <other_name>Acthar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has the ability to understand and sign the informed consent document

          -  Subject is 18 years of age or older

          -  Subject can be male or female

          -  Subject has negative Purified Protein Derivative (Tuberculosis skin test) or
             quantiferon TB Gold Test (blood test for TB) testing done in 3 months

          -  Subject has active ocular inflammation in at least one eye

          -  Subject has visual acuity in at least one eye of 20/400 or better.

          -  Subject has a history of glaucoma or has actively treated glaucoma

          -  Subject is willing and able to comply with the study procedures

          -  Female subjects of childbearing potential must not be pregnant or breast-feeding, must
             have a negative pregnancy test at screening and must be willing to undergo pregnancy
             testing throughout the study

        Exclusion Criteria:

          -  Subject has any ocular infection

          -  Subject has any systemic infection

          -  Participant has documented immunocompromised or immune-incompetent state

          -  Subject has any ocular co-morbidity than prevents assessment of intraocular
             inflammation

          -  Subject has had any intra-ocular surgery in previous 6 weeks

          -  Subject has any planned elective surgery ocular or systemic during study duration

          -  Subject is pregnant or breast-feeding

          -  Subject had a recent vaccination with live or attenuated vaccines

          -  Subject has a sensitivity to Porcine derived proteins

          -  Subject has a medical history which is a contraindication to receiving H.P. Acthar
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace L Clarke</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampa Bay Uveitis Center, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tampa Bay Uveitis Center</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <results_first_submitted>November 23, 2017</results_first_submitted>
  <results_first_submitted_qc>June 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2018</results_first_posted>
  <last_update_submitted>June 29, 2018</last_update_submitted>
  <last_update_submitted_qc>June 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma associated with uveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Anterior</mesh_term>
    <mesh_term>Iridocyclitis</mesh_term>
    <mesh_term>Uveitis, Posterior</mesh_term>
    <mesh_term>Uveitis, Intermediate</mesh_term>
    <mesh_term>Pars Planitis</mesh_term>
    <mesh_term>Scleritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period was 06/31/2016 through 08/10/2016
Active follow-up period 06/31/2016 through 12/07/2016
The study was conducted at 1 site Tampa Bay Uveitis Center, LLC 5800 49th Street North, St Petersburg Fl 33709: Outpatient Medical Clinic</recruitment_details>
      <pre_assignment_details>The patient after consent was given, were required to have their medical records reviewed and have screening laboratory evaluations</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>H.P. Acthar Subcutaneous Gel Injection</title>
          <description>For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION: Subcutaneous injection twice weekly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>H.P. Acthar Subcutaneous Gel Injection</title>
          <description>For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION: Subcutaneous injection twice weekly</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Photographic Haze Reduced to Grade 0 or Down 2 Steps Documented With Fundus Photography</title>
        <description>Subjects will have fundus photography at baseline and 12 weeks. Intermediate uveitis is graded by haze; it is done using the photographic scale: grades 0-4 (lower values are a better outcome), utilized by the SUN criteria, based on the Nussenblatt photographic vitreous haze scale</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H.P. Acthar Subcutaneous Gel Injection</title>
            <description>For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION: Subcutaneous injection twice weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Photographic Haze Reduced to Grade 0 or Down 2 Steps Documented With Fundus Photography</title>
          <description>Subjects will have fundus photography at baseline and 12 weeks. Intermediate uveitis is graded by haze; it is done using the photographic scale: grades 0-4 (lower values are a better outcome), utilized by the SUN criteria, based on the Nussenblatt photographic vitreous haze scale</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1 Step of VH Improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 Step of VH</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No VH Improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Improvement of Macular Edema</title>
        <description>Clinically Significant Uveitic Macular Edema: Clinical Improvement of Macular Edema with OCT Documentation of central foveal thickness &lt; 300 microns</description>
        <time_frame>12 weeks</time_frame>
        <population>0</population>
        <group_list>
          <group group_id="O1">
            <title>H.P. Acthar Subcutaneous Gel Injection</title>
            <description>For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION: Subcutaneous injection twice weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Improvement of Macular Edema</title>
          <description>Clinically Significant Uveitic Macular Edema: Clinical Improvement of Macular Edema with OCT Documentation of central foveal thickness &lt; 300 microns</description>
          <population>0</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease in Central Foveal Thickness &lt;300</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease in central Fovea &gt; 300 Microns</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>H.P. Acthar Subcutaneous Gel Injection</title>
          <description>For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION: Subcutaneous injection twice weekly</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Grace Levy Clarke</name_or_title>
      <organization>Tampa Bay Uveitis Center, LLC</organization>
      <phone>855 798 8393</phone>
      <email>grace@tampabayuveitis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

